Naos fund reaps life science and biotech rewards


Investments in Australian biotech and life sciences companies helped lift the Naos Emerging Long Short Equity Fund in March. The fund, which focuses exclusively on Australian equities, rose 9.33% in March, after a 11.83% gain in February.

“We don’t follow the market performance-wise, we look for big industry themes,” said fund manager Sebastian Evans.

Naos has been eyeing the biotech and life-sciences sector for more than three years. The Australian equities market is heavy on resource and financial-services companies and life sciences generally get lost in the shuffle, Evans said.

Two holdings in particular helped